225
Alzheimer’s appears 25 years after the first signs of abnormalities of amyloid, a protein that accumulates in the brain in patients with this pathology, and therefore from the onset of symptoms. For this reason, US researchers have set themselves an ambitious question and goal: is it possible to prevent the disease by administering targeted drugs to people who do not yet have any symptoms?
Drugs that can address this challenge are antibodies developed to target and eliminate amyloid-β proteins in the brain, proteins that wedge into toxic masses called plaques.